Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER H WIN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1124040209
CMS profile
141025
Location
ARCADIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$408.04

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $408.04 22

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER H WIN

NPI 1124040209 · CMS profile ID 141025

Allopathic & Osteopathic Physicians / Ophthalmology

ARCADIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER H WIN, NPI 1124040209, CMS profile ID 141025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PETER H WIN, NPI 1124040209, CMS profile ID 141025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PETER H WIN, NPI 1124040209, CMS profile ID 141025, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $408.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sun Pharmaceutical Industries Inc. $24.1212/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876383 CMS
Apellis Pharmaceuticals, Inc. $22.2712/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964259507 CMS
Regeneron Healthcare Solutions, Inc. $33.6211/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927476499 CMS
Sun Pharmaceutical Industries Inc. $23.6610/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876377 CMS
Regeneron Healthcare Solutions, Inc. $32.9508/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927476493 CMS
Sun Pharmaceutical Industries Inc. $5.3408/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876371 CMS
Mallinckrodt Hospital Products Inc. $18.9308/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937532737 CMS
Sun Pharmaceutical Industries Inc. $25.0408/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876365 CMS
Sun Pharmaceutical Industries Inc. $19.1006/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876359 CMS
Bausch & Lomb Americas Inc. $20.2306/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957525959 CMS
Mallinckrodt Hospital Products Inc. $20.7405/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937532735 CMS
Genentech USA, Inc. $21.7505/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950776891 CMS
Spark Therapeutics, Inc. $21.4505/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938541617 CMS
Novartis Pharmaceuticals Corporation $21.7505/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894453769 CMS
EYEVANCE PHARMACEUTICALS LLC $14.4804/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896704993 CMS
Genentech USA, Inc. $21.8204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950788843 CMS
Sun Pharmaceutical Industries Inc. $5.4404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876353 CMS
Alimera Sciences, Inc. $11.2703/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896603017 CMS
Sun Pharmaceutical Industries Inc. $5.1403/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876347 CMS
Sun Pharmaceutical Industries Inc. $15.0002/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876341 CMS
Alcon Vision LLC $18.6702/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905115645 CMS
Sun Pharmaceutical Industries Inc. $5.2701/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876335 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $376.26 27
PY2020 $369.48 18
PY2021 $467.02 31
PY2022 $408.04 22
PY2023 $529.17 23
PY2024 $307.75 14
PY2025 $396.97 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,800.65 3
PY2025 Principal investigator $1,018,714.70 358
PY2024 Recipient $41,692.12 4
PY2024 Principal investigator $792,747.79 884
PY2023 Recipient $95,996.85 6
PY2023 Principal investigator $408,946.29 24
PY2022 Recipient $123,777.97 8
PY2022 Principal investigator $843,108.89 22
PY2021 Principal investigator $927,697.26 16
PY2020 Principal investigator $132,922.86 4
PY2019 Principal investigator $29,997.25 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

888 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451936
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082451998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452256
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452260
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452264
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452268
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452270
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452272
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452274
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452276
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452278
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452280
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452296
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452330
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452334
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452342
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452348
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452350
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452364
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452376
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452380
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452390
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452394
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452396
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452402
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452404
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452408
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452454
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452486
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452490
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452500
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452502
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452556
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452648
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.68 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452702
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452726
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452864
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452878
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452936
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082452998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.74 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $396.99 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $363.17 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.83 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $206.46 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.12 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $361.57 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453220
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $378.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $466.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.42 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $468.88 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.29 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $297.58 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $469.71 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.47 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $304.04 12/26/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082453256
Principal investigator 1 Kyowa Kirin, Inc. $2,865.13 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482273
Principal investigator 1 Kyowa Kirin, Inc. $2,548.02 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482275
Principal investigator 1 Kyowa Kirin, Inc. $2,677.21 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482277
Principal investigator 1 Kyowa Kirin, Inc. $2,677.21 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482279
Principal investigator 1 Kyowa Kirin, Inc. $2,865.13 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482281
Principal investigator 1 Kyowa Kirin, Inc. $326.25 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482283
Principal investigator 1 Kyowa Kirin, Inc. $3,800.16 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482285
Principal investigator 1 Kyowa Kirin, Inc. $5,586.71 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482287
Principal investigator 1 Kyowa Kirin, Inc. $2,548.02 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482289
Principal investigator 1 Kyowa Kirin, Inc. $326.25 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482291
Principal investigator 1 Kyowa Kirin, Inc. $1,574.35 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482293
Principal investigator 1 Kyowa Kirin, Inc. $1,574.35 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482295
Principal investigator 1 Kyowa Kirin, Inc. $1,574.35 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482297
Principal investigator 1 Kyowa Kirin, Inc. $1,574.35 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482299
Principal investigator 1 Kyowa Kirin, Inc. $1,574.35 12/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482301
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482243
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482245
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482247
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482249
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482251
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482253
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482255
Principal investigator 1 Kyowa Kirin, Inc. $3,161.73 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482257
Principal investigator 1 Kyowa Kirin, Inc. $5,524.07 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482259
Principal investigator 1 Kyowa Kirin, Inc. $2,974.68 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482261
Principal investigator 1 Kyowa Kirin, Inc. $2,394.67 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482263
Principal investigator 1 Kyowa Kirin, Inc. $2,974.68 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482265
Principal investigator 1 Kyowa Kirin, Inc. $5,524.07 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482267
Principal investigator 1 Kyowa Kirin, Inc. $2,732.67 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482269
Principal investigator 1 Kyowa Kirin, Inc. $5,921.80 12/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482271
Principal investigator 1 Kyowa Kirin, Inc. $2,632.84 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482185
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482187
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482189
Principal investigator 1 Kyowa Kirin, Inc. $2,665.47 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482191
Principal investigator 1 Kyowa Kirin, Inc. $2,420.13 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482193
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482195
Principal investigator 1 Kyowa Kirin, Inc. $2,632.84 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482197
Principal investigator 1 Kyowa Kirin, Inc. $2,665.47 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482199
Principal investigator 1 Kyowa Kirin, Inc. $2,420.13 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482201
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482203
Principal investigator 1 Kyowa Kirin, Inc. $2,632.84 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482205
Principal investigator 1 Kyowa Kirin, Inc. $2,665.47 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482207
Principal investigator 1 Kyowa Kirin, Inc. $2,277.88 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482209
Principal investigator 1 Kyowa Kirin, Inc. $2,548.02 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482211
Principal investigator 1 Kyowa Kirin, Inc. $2,865.13 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482213
Principal investigator 1 Kyowa Kirin, Inc. $2,277.88 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482215
Principal investigator 1 Kyowa Kirin, Inc. $4,820.67 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482217
Principal investigator 1 Kyowa Kirin, Inc. $3,800.16 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482219
Principal investigator 1 Kyowa Kirin, Inc. $2,277.88 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482221
Principal investigator 1 Kyowa Kirin, Inc. $4,820.67 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482223
Principal investigator 1 Kyowa Kirin, Inc. $2,420.13 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482225
Principal investigator 1 Kyowa Kirin, Inc. $2,632.84 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482227
Principal investigator 1 Kyowa Kirin, Inc. $6,296.10 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482229
Principal investigator 1 Kyowa Kirin, Inc. $4,723.05 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482231
Principal investigator 1 Kyowa Kirin, Inc. $4,723.05 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482233
Principal investigator 1 Kyowa Kirin, Inc. $4,723.50 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482235
Principal investigator 1 Kyowa Kirin, Inc. $4,723.50 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482237
Principal investigator 1 Kyowa Kirin, Inc. $3,148.70 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482239
Principal investigator 1 Kyowa Kirin, Inc. $1,574.75 12/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482241
Recipient Genentech, Inc. $6,548.00 12/17/2024 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1133363025
Principal investigator 1 Kyowa Kirin, Inc. $1,574.35 12/11/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 11/22/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) No dispute reported 06/30/2026 1082445632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 11/22/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) No dispute reported 06/30/2026 1082445634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 11/22/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) No dispute reported 06/30/2026 1082445636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,713.52 11/22/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) No dispute reported 06/30/2026 1082445638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 11/06/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082443780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/06/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082443782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 11/06/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082443784
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482159
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482161
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482163
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482165
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482167
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482169
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482171
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482173
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482175
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482177
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482179
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 10/24/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482181
Principal investigator 1 Kyowa Kirin, Inc. $2,632.84 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482137
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482139
Principal investigator 1 Kyowa Kirin, Inc. $2,420.13 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482141
Principal investigator 1 Kyowa Kirin, Inc. $2,420.13 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482143
Principal investigator 1 Kyowa Kirin, Inc. $2,632.84 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482145
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482147
Principal investigator 1 Kyowa Kirin, Inc. $2,665.47 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482149
Principal investigator 1 Kyowa Kirin, Inc. $2,632.84 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482151
Principal investigator 1 Kyowa Kirin, Inc. $2,665.47 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482153
Principal investigator 1 Kyowa Kirin, Inc. $2,420.13 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482155
Principal investigator 1 Kyowa Kirin, Inc. $5,008.59 09/18/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482157
Principal investigator 1 Kyowa Kirin, Inc. $5,524.07 09/16/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482133
Principal investigator 1 Kyowa Kirin, Inc. $2,732.67 09/16/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482135
Recipient Genentech, Inc. $17,190.00 06/25/2024 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1133363023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,680.00 05/09/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082425823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42,369.84 05/09/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082425825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,633.50 04/05/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082424355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26,730.00 04/05/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082424357
Recipient Genentech, Inc. $9,855.00 03/21/2024 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1133363021
Principal investigator 1 Kyowa Kirin, Inc. $2,000.00 03/13/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482127
Principal investigator 1 Kyowa Kirin, Inc. $5,000.00 03/13/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482129
Principal investigator 1 Kyowa Kirin, Inc. $6,747.00 03/13/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema No dispute reported 06/30/2026 1129482131
Principal investigator 1 Kyowa Kirin, Inc. $11,550.00 02/27/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,679.44 02/19/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082418049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,309.16 02/12/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082417251
Principal investigator 1 Kyowa Kirin, Inc. $2,000.00 02/07/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482121
Principal investigator 1 Kyowa Kirin, Inc. $6,747.00 02/07/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482123
Principal investigator 1 Kyowa Kirin, Inc. $5,000.00 02/07/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482125
Recipient Hexal AG $8,099.12 01/25/2024 Covered Recipient Physician CSOK583A12301 No dispute reported 06/30/2026 1085610618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,169.92 01/22/2024 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1082415033
Principal investigator 1 Kyowa Kirin, Inc. $2,750.00 01/19/2024 Non-covered Recipient Entity
WIN RETINA
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1129482117
Principal investigator 1 Roche TCRC, Inc. $7,151.40 01/17/2024 Non-covered Recipient Entity
Win Retina
Oral Treatment of NPDR No dispute reported 06/30/2026 1133478022